Stock TCRX TSCAN THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

TScan Therapeutics, Inc. Share Price

Equities

TCRX

US89854M1018

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 21:00:00 26/04/2024 BST 		5-day change 1st Jan Change
7.32 USD +0.41% Intraday chart for TScan Therapeutics, Inc. +7.33% +25.56%
04-19 TScan Therapeutics Closes $150.1 Million Securities Offering MT
04-17 TScan Therapeutics Prices $150.1 Million Public Offering of Shares, Warrants MT

Financials

Sales 2024 * 17.6M 1.41B Sales 2025 * 15.66M 1.25B Capitalization 369M 29.52B
Net income 2024 * -103M -8.25B Net income 2025 * -119M -9.53B EV / Sales 2024 * 17 x
Net cash position 2024 * 68.9M 5.52B Net cash position 2025 * 66.72M 5.34B EV / Sales 2025 * 19.3 x
P/E ratio 2024 *
-7.12 x
P/E ratio 2025 *
-6.48 x
Employees 154
Yield 2024 *
-
Yield 2025 *
-
Free-Float 90.66%
More Fundamentals * Assessed data

Chart TScan Therapeutics, Inc.

Dynamic Chart

Latest news about TScan Therapeutics, Inc.

TScan Therapeutics Closes $150.1 Million Securities Offering MT
TScan Therapeutics Prices $150.1 Million Public Offering of Shares, Warrants MT
TScan Therapeutics Launches $125 Million Securities Offering; Shares Rise After Hours MT
TScan Therapeutics, Inc. Provides Clinical Pipeline Update and Highlights Near-Term Priorities CI
TScan Therapeutics, Inc. Announces Executive Changes CI
Barclays Raises Price Target on TScan Therapeutics to $9 From $7, Keeps Overweight Rating MT
TScan Therapeutics Files $300 Million Mixed-Securities Shelf MT
TScan Therapeutics Q4 Net Loss Narrows, Revenue Increases MT
Wedbush Adjusts TScan Therapeutics Price Target to $10 From $9, Maintains Outperform Rating MT
TScan Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
TScan Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
TScan Therapeutics Names Jason Amello as Finance Chief MT
TScan Therapeutics, Inc. Appoints Jason A. Amello as Chief Financial Officer CI
Tscan Therapeutics, Inc. Presents Initial Phase 1 Clinical Results on TSC-100 and TSC-101 At the 65Th American Society of Hematology Annual Meeting and Exposition CI
TScan Therapeutics Appoints R. Keith Woods to its Board of Directors CI
More news

Analyst Recommendations on TScan Therapeutics, Inc.

Barclays Raises Price Target on TScan Therapeutics to $9 From $7, Keeps Overweight Rating MT
Wedbush Adjusts TScan Therapeutics Price Target to $10 From $9, Maintains Outperform Rating MT
Wedbush Lifts TScan Therapeutics' Price Target to $9 From $8, Keeps Outperform Rating MT
Wedbush Starts TScan Therapeutics at Outperform With $8 Price Target, Notes Cadence of Near-Term Catalysts, Differentiated Technology Capabilities MT
HC Wainwright Lowers TScan Therapeutics Price Target to $15 From $21, Maintains Buy Rating MT
More recommendations

Press releases TScan Therapeutics, Inc.

TScan Therapeutics Announces Upcoming Presentations at the 2024 American Society of Clinical Oncology Annual Meeting GL
TScan Therapeutics Announces Exercise of Underwriters' Option to Purchase Additional Shares GL
TScan Therapeutics Announces Upcoming Presentations at the American Society of Gene and Cell Therapy 27th Annual Meeting GL
TScan Therapeutics Announces Closing of Upsized Public Offering AQ
TScan Therapeutics Announces Closing of Upsized Public Offering GL
More press releases

Quotes and Performance

1 day+0.41%
1 week+7.33%
Current month-7.81%
1 month-11.81%
3 months+45.82%
6 months+115.29%
Current year+25.56%
More quotes

Highs and lows

1 week
6.74
Extreme 6.74
7.55
1 month
6.58
Extreme 6.58
8.16
Current year
4.64
Extreme 4.64
9.00
1 year
1.62
Extreme 1.62
9.00
3 years
1.45
Extreme 1.45
14.71
5 years
1.45
Extreme 1.45
14.71
10 years
1.45
Extreme 1.45
14.71
More quotes

Managers and Directors - TScan Therapeutics, Inc.

Managers TitleAgeSince
Gavin MacBeath CEO
 Chief Executive Officer 54 30/11/18
Jason Amello DFI
 Director of Finance/CFO 55 01-28
Justin McCue CTO
 Chief Tech/Sci/R&D Officer - 12-03
Members of the board TitleAgeSince
Timothy Barberich CHM
 Chairman 76 28/02/19
Stephen Biggar BRD
 Director/Board Member 53 28/02/21
Gavin MacBeath CEO
 Chief Executive Officer 54 30/11/18
More insiders

Quotes

Date Price Change Volume
26/04/24 7.32 +0.41% 92,052
25/04/24 7.29 -1.22% 107,354
24/04/24 7.38 +1.65% 90,771
23/04/24 7.26 +1.97% 208,344
22/04/24 7.12 +4.40% 173,228

Delayed Quote Nasdaq, April 26, 2024 at 09:00 pm

More quotes

Company Profile

TScan Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of T cell receptor-engineered T cell (TCR-T), therapies for the treatment of patients with cancer. The Company’s lead TCR-T therapy candidates, TSC-100 and TSC-101, are in clinical development for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation. The Company is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors. The Company has developed and continues to build its ImmunoBank, a collection of solid tumor targets across different Human leukocyte antigens (HLAs) types in the TCR field. The Company is advancing approximately six solid tumor programs: TSC-204, TSC-200, TSC-203, TSC-201, TSC-202 and TSC-205.
Sector
Biotechnology & Medical Research
Calendar
06/05/2024 - Q1 2024 Earnings Release (Projected)
More about the company

Income Statement Evolution

More financial data

Ratings for TScan Therapeutics, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
7.32 USD
Average target price
11.6 USD
Spread / Average Target
+58.47%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
TSCAN THERAPEUTICS, INC. Stock TScan Therapeutics, Inc.
+25.56% 369M
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.51% 42.75B
LONZA GROUP AG Stock Lonza Group AG
+49.22% 41.61B
MODERNA, INC. Stock Moderna, Inc.
+8.57% 41.34B
CELLTRION, INC. Stock Celltrion, Inc.
-12.36% 26.59B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+8.92% 25.49B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-25.13% 18.12B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+29.17% 12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.12% 11.76B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+6.35% 11B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. TCRX Stock